All articles tagged with #weight loss
ACE CEO Cedric X. Bryant says older adults using GLP-1 weight-loss meds should prioritize preserving strength, physical function and lean mass through regular resistance training (2-3 days/week; six-to-ten exercises; 1-3 sets; 8-15 reps) and adequate protein (roughly 1.2-1.6 g/kg/day), with targets tailored by age and health; programming should be individualized and safety-conscious, especially for those in their 70s and beyond.
Hims & Hers, the telehealth company built on selling GLP-1 weight-loss drugs online, plans a pivot into wellness and longevity, including potentially FDA-regulated peptides. The founder-CEO aims to source peptides in the U.S. and lean on its mass-marketing platform to push broader wellness products, signaling a transition from prescription-focused care toward a broader wellness business amid regulatory scrutiny.
Intermittent fasting can aid weight loss for some people, but it’s not universal. Start with shorter windows (like 12:12) and increase gradually, focus on timing rather than deprivation, and prioritize high‑quality foods. Be mindful of overeating during eating periods, and recognize that women may need shorter fasting windows. IF isn’t recommended for children, pregnant/breastfeeding individuals, or certain medical conditions without medical supervision, and sustainability and personalization are key for long-term success.
The Washington Post reports that some people with anorexia, bulimia, or binge eating disorder are using GLP-1 weight-loss medications, prompting alarm from doctors about safety and the need for careful monitoring of vulnerable patients, as anecdotal stories highlight the risk and complexity of treating eating disorders with these drugs.
Eli Lilly's retatrutide, a weekly triple hormone receptor agonist (GLP-1, GIP, glucagon), produced an average 28.3% weight loss (70.3 lb) over 80 weeks at the 12 mg dose in a Phase 3 trial of 2,339 adults with obesity or overweight and a weight-related comorbidity. The 12 mg group lost more weight than the 9 mg and 4 mg groups, with 65.3% reaching a BMI below 30 and 37.5% starting with BMI ≥40; 45.3% achieved at least 30% weight loss. Retatrutide’s weight loss appears to exceed current drugs Wegovy and Zepbound. The drug, which combines GLP-1 and GIP with glucagon, also improved cardio-metabolic risk factors, though side effects such as nausea, diarrhea, constipation, and vomiting increased with dose.
Lilly’s triple-G obesity drug retatrutide met primary endpoints in Phase 3 TRIUMPH-1, delivering up to 28.3% weight loss at 80 weeks for the highest dose on the efficacy estimand (vs 2.2% for placebo). On the treatment-regimen estimand, weight losses were 17.6% (4 mg), 23.7% (9 mg) and 25% (12 mg) with placebo at 3.9%. A Week 104 readout for the top dose reached 29.9% among patients who stayed on therapy. The topline did not include sleep apnea or osteoarthritis pain data. Safety showed higher discontinuations at the high dose (11.3% vs 4.9% placebo) and notable dysesthesia (20.9% at high dose); GI adverse events were more common at the low dose. Analysts said the results meet key endpoints but didn’t exceed expectations, and Lilly is eyeing possible FDA submission this year amid competition from Wegovy and other obesity drugs.
Eli Lilly announced topline TRIUMPH-1 results for retatrutide, a first-in-class GIP/GLP-1/glucagon triple agonist, in adults with obesity or overweight and comorbidities. Across 4 mg, 9 mg, and 12 mg doses, participants achieved meaningful weight loss at 80 weeks (4 mg: 19.0%, 9 mg: 25.9%, 12 mg: 28.3%), with the 12 mg group averaging 70.3 lb and 45.3% reaching ≥30% weight loss; BMI ≤22 was achieved by 65.3% at Week 80. Some participants with higher BMI continued losing weight in extensions, reaching about 30% total body weight loss over roughly two years. All arms met primary and key secondary endpoints, and the follow-on extension data covered up to 104 weeks. Safety disclosures mirror warnings associated with Lilly's obesity medicines.
Lilly reports that retatrutide, a triple agonist of GLP-1, GIP, and glucagon, produced up to about 85 pounds (roughly 30% of body weight) loss in a phase 3 trial of ~2,300 people with obesity or overweight, with the highest weekly dose averaging 28% weight loss over 80 weeks (some participants continued to 104 weeks). If approved, it could surpass current GLP-1 meds and aid patients who don’t respond to those drugs. Side effects include nausea, GI issues, skin sensations, and UTIs. Full results haven’t been published in a medical journal, and an FDA filing could occur as early as this year.
Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.
Orforglipron, a once-daily pill-based GLP-1 weight‑loss drug, could sustain weight loss and cut costs versus injections like Wegovy and Mounjaro. In a small trial, switching to orforglipron after initial weight loss reduced weight regain markedly (about 26% with orforglipron vs 50%+ on placebo for Mounjaro; about 21% vs 62% for Wegovy) while preserving health benefits; US monthly price is roughly $149–$299 vs over $1,000 for Mounjaro, and the UK has not yet licensed it but expects approval around late 2026–early 2027.
Mindy Kaling says the online scrutiny of her weight loss is understandable but not fun, stressing that health goals—like staving off diabetes and living longer for her children—drive the changes, while noting she doesn’t dwell on body-shaming as she works on TV projects such as Running Point and Not Suitable for Work.
Mindy Kaling says her weight loss is about health and longevity for her children, not vanity, and she acknowledges scrutiny over her changing body while hinting she may write more about it in the future, noting she wants to stave off diabetes given family history.
Mindy Kaling says her weight loss is about health and longevity, not vanity, aiming to live at least 20 more years for her three young children; she follows a sustainable routine—walking 15–20 miles weekly, hiking, yoga, and weight training—while avoiding weighing herself and focusing on how she feels rather than numbers.
As GLP-1 medications used for weight loss (e.g., Ozempic, Wegovy, Mounjaro) help quiet food cues, some users report a heightened obsession with fragrances and stronger scent perception. Experts suggest reduced food reward may make non-food senses more salient, potentially involving GLP-1 receptors in the olfactory system; while anecdotes are growing, large controlled studies are still needed. A few FAERS reports mention parosmia, which could also influence fragrance preferences.
A BuzzFeed News piece compiles Reddit anecdotes about stopping GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) and notes a BMJ meta-analysis finding that people who stop weight loss meds regain weight about four times as fast as those leaving behavioral programs, typically returning to baseline in about 1.7 years. The responses span a spectrum: hunger and food cravings return; some report hair loss or energy dips; many regain weight, but others credit lasting lifestyle changes like mindful eating, calorie tracking, and regular exercise for maintaining weight or easing off gradually. The piece highlights ongoing questions about whether GLP-1s are a temporary boost or a long term tool, and invites more personal experiences.